27.4 C
New York
Friday, June 14, 2024

J&J’s Janssen to shut a part of its vaccine division -Telegraaf By Reuters

Must read

AMSTERDAM (Reuters) -Johnson & Johnson’s Janssen division, which helped to develop its single-dose COVID-19 vaccine, will shut a lot of its vaccine analysis and improvement operations within the Netherlands, newspaper De Telegraaf reported.

In an emailed response on Wednesday, Johnson & Johnson (NYSE:) confirmed plans to exit a few of its vaccine analysis and improvement programmes, which it stated it had initially disclosed in its 2023 second-quarter outcomes.

“We additionally frequently assess our international footprint, together with within the Netherlands, to make sure it meets our present and evolving scientific wants,” Johnson & Johnson stated, including that its facility in Leiden, Netherlands was an “vital website”.

De Telegraaf reported that 2,500 folks labored at Janssen within the Netherlands, 1 / 4 of which had been within the part specialising in infectious ailments and vaccines.

It isn’t clear what number of jobs are in danger.

J&J’s comparatively giant Dutch vaccine operation stems partially from its $2.1 billion acquisition in 2011 of vaccine maker Crucell.

See also  Anti-Israeli protesters eliminated after storming Russia's Dagestan airport By Reuters

J&J stated throughout second quarter earnings in July it might stop improvement of vaccines for respiratory syncytial virus (RSV), hepatitis, and HIV. It stated on Wednesday it’s persevering with work on a vaccine in opposition to E.coli bacterial infections.

The Janssen COVID-19 vaccine didn’t carry out in addition to the corporate hoped in high-income international locations due partially to worries about blood clots as a uncommon facet impact. In June 2023, the FDA revoked emergency-use authorization for the vaccine at Janssen’s request.

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News